Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.4.0.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Condensed Consolidated Statements Of Operations    
Revenues, net $ 230,413 $ 275,465
Operating expenses:    
Cost of implants and other costs 40,453 11,500
Selling, general and administrative 391,239 $ 238,068
Termination of licensing agreement 132,804
Depreciation and amortization 573 $ 33,566
Total operating expenses 565,069 283,134
Net loss from operations (334,656) (7,669)
Other income (expenses):    
Interest expense, net (165,232) (99,849)
Gain on change in fair value of derivative liability (28,697) (95,656)
Total other income (expenses) (193,929) (195,505)
Loss before income taxes $ (528,585) $ (203,174)
Income taxes
Net loss $ (528,585) $ (203,174)
Net loss per common share, basic and diluted $ (0.00) $ (0.00)
Weighted average number of common shares outstanding, basic and diluted 164,938,457 149,134,223